Sundia MediTech

What Sundia MediTech does

BioDuro (operating brand of Sundia MediTech) is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end pharmaceutical services from drug discovery through commercial manufacturing. Founded in 1996 and headquartered in Irvine, California, with a global footprint across 8 campuses, BioDuro operates as a platform-plus-modules architecture built on three service pillars—Discovery (chemistry, DMPK, biology), Drug Substance (process R&D, scale-up synthesis, API manufacturing), and Drug Product (preformulation, formulation, commercial manufacturing). The company supports specialized technology platforms for emerging modalities including Antibody-Drug Conjugates (ADC), PROTAC, DNA-Encoded Library screening, peptide chemistry, and NASH/MASH preclinical models. IND-enabling services span FDA, NMPA, and other major regulatory jurisdictions.

The company serves over 1,500 active customers globally, primarily pharmaceutical and biotechnology companies ranging from large pharma to clinical-stage biotech, with academic and research institutions as a secondary segment. BioDuro employs 2,000+ scientists worldwide according to its website, while firmographic records for the Sundia MediTech entity indicate 501-1,000 employees (suggesting the broader global workforce operates across affiliated entities). The revenue model is contract-based fee-for-service with multi-year project engagements, custom-quoted by scope, duration, and complexity. GTM is enterprise field sales targeting pharmaceutical R&D leadership and procurement directly, supplemented by industry events, scientific webinars, and content marketing.

Disclosed funding history for Sundia MediTech totals $10.5M across a 2005 seed/Series A round from IDG Capital ($2.5M) and a 2008 Series B led by AsiaVest Partners and IDG Capital ($8M), with a 2015 undisclosed investment from Darwin Venture Management. No parent company is disclosed, but the website references 'Our Investors,' confirming institutional backing. Recent activity includes strategic partnerships with CTI Biotechnology (April 2026) and Gilva Therapeutics (May 2026), along with scientific advisory appointments of Dr. Andrew Thomas and Dr. Stevan Djuric (March 2026). CEO is Jim Li. BioDuro marked its 30th anniversary with a Shanghai symposium in June 2025 under the theme 'Accelerating Breakthroughs Through Innovation.'

Name

Sundia MediTech

Legal name

BioDuro

Website

https://sundia.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BioDuro (Sundia MediTech) is a fully integrated CRDMO providing end-to-end drug discovery, development, and manufacturing services across 8 global campuses with 2,000+ scientists, serving over 1,500 pharmaceutical and biotechnology customers worldwide.

Ownership category

akta.pro rank

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research and Development Services: Fee-for-service model providing drug discovery and development services including chemistry, DMPK, biology, and preclinical studies. Revenue generated through project-based contracts with pharmaceutical and biotechnology companies.
2. Drug Substance Manufacturing: Manufacturing services for APIs, RSMs, and intermediates at kilo and pilot scale, including scale-up synthesis and IND enabling capabilities for FDA, NMPA and other regulatory filings.
3. Drug Product Development and Manufacturing: Formulation development, analytical services, and manufacturing for solid oral dosage forms from clinical through commercial stages.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Sundia MediTech is a Contract Research, Development and Manufacturing Organization (CRDMO) that provides integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company delivers end-to-end capabilities spanning Discovery (Chemistry, DMPK, Biology), Drug Substance manufacturing, and Drug Product development, supported by specialized platforms for antibody-drug conjugates, peptides, PROTAC, DNA-encoded libraries, and disease-specific preclinical models.

Product overview

Sundia MediTech (operating as BioDuro) is a fully integrated Global CRDMO (Contract Research, Development, and Manufacturing Organization) providing end-to-end pharmaceutical and biotechnology research services. The company operates as a platform-plus-modules architecture with three core service pillars (Discovery, Drug Substance, Drug Product) supported by specialized platforms including Antibody-Drug Conjugate, Peptide, PROTAC, DNA-Encoded Library (DEL), Integrated Drug Discovery, Solution Engine, IND Enabling, NASH Mouse Models, and Compound Management. The unified platform approach enables seamless integration from target identification through preclinical candidate selection to IND filing, serving over 1,500 active customers globally across 8 campuses with 2,000+ scientists. BioDuro was founded in 1996 and is headquartered in Irvine, CA.

Differentiator

Problem solved

Functional benefit

Brands

• Solution Engine: Tailored engine for small molecular drug discovery, unlocking exponential possibilities screening billions of small molecules.

Products and services

• Discovery Services Comprehensive drug discovery services covering Chemistry (peptide chemistry, medicinal chemistry, computational chemistry, synthetic chemistry, analytical chemistry, scale-up chemistry, fragment-based drug discovery), DMPK (in vivo PK/TK, in vitro ADME, bioanalytical services, toxicity studies, large molecule development), and Biology (assay development, biochemical and cellular assays, ligand binding assays, protein science, SPR biophysics, biologics) for pharmaceutical and biotechnology clients.
• Drug Substance Services End-to-end drug substance services including process R&D (flow chemistry, sugar chemistry, peptide chemistry, preparative purification, process safety assessment), scale-up synthesis, and drug substance manufacturing at kilo and pilot scale for APIs, RSMs, and intermediates, with QA and EHS support for pharmaceutical clients.
• Drug Product Services Drug product development services including preformulation, formulation development (hot melt extrusion, spray dried dispersion, amorphous solid dispersion, bioavailability enhancement, modified release), analytical services, and drug product manufacturing for clinical and commercial stages, serving pharmaceutical and biotechnology companies.
• Oncology Services Preclinical oncology research services including PDX (patient-derived xenograft), CDX (cell-derived xenograft), orthotopic models, syngeneic models, humanized mouse models, CAR-T and CAR-NK mouse models, ELISA assays, and in vitro assays for oncology drug developers.
• Pharmacology Services Preclinical pharmacology services covering immunology and inflammation, metabolic disorders, MASH/NASH mouse models, respiratory diseases, neuroscience, and safety pharmacology for drug developers across therapeutic areas.
• Antibody-Drug Conjugate Platform Specialized platform for antibody-drug conjugate (ADC) development and manufacturing services supporting pharmaceutical and biotechnology clients working on targeted cancer therapeutics.
• Peptide Platform Comprehensive peptide chemistry platform for peptide drug discovery and development, including custom peptide synthesis and scale-up services for pharmaceutical and biotechnology companies.
• PROTAC Platform PROTAC (Proteolysis-Targeting Chimera) technology platform for targeted protein degradation drug discovery, enabling pharmaceutical and biotechnology clients to develop therapies against previously undruggable targets.
• DNA-Encoded Library (DEL) Platform DNA-encoded library technology platform for high-throughput screening of billions of small molecules for hit generation, supporting accelerated lead discovery for pharmaceutical and biotechnology clients.
• Integrated Drug Discovery Platform Fully integrated drug discovery platform providing comprehensive services from target identification to preclinical candidate compound (PCC), combining synthetic chemistry, biology, DMPK, and other disciplines under one roof for pharmaceutical and biotechnology clients.
• Solution Engine Tailored engine for small molecular drug discovery enabling screening of billions of small molecules with exponential possibilities for hit identification and lead optimization by pharmaceutical and biotechnology clients.
• IND Enabling Services IND (Investigational New Drug) enabling services to support regulatory filings with FDA, NMPA, and other major agencies for pharmaceutical and biotechnology companies advancing candidates to clinical trials.
• MASH/NASH Mouse Models Advanced preclinical NASH (Metabolic dysfunction-Associated SteatoHepatitis) mouse models providing clinical relevance with shortened timelines for metabolic disease drug developers.
• Compound Management Automated, flexible, and customized compound management platform for efficient handling and storage of chemical compounds during drug discovery for pharmaceutical and biotechnology clients.

Quantifiable outcome

• Accelerated breakthroughs through integrated innovation

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Two partnerships are on record, tiered core.

• CTI BiotechnologycoreStrategic or Co-development Partner · 28 April 2026BioDuro and CTI Biotechnology entered a strategic partnership to accelerate preclinical drug development. This collaboration leverages BioDuro's integrated CRDMO capabilities with CTI Biotechnology's expertise to provide comprehensive preclinical development solutions for clients.
• Gilva TherapeuticscoreStrategic or Co-development PartnerBioDuro congratulated Gilva Therapeutics on advancing GV-100 into Phase I Clinical Development in Australia, indicating an ongoing partnership supporting the client's clinical advancement program.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Medpace: Mid-sized clinical CRO serving biotech/small pharma. Comparable customer segment and quality reputation, but concentrated in clinical rather than preclinical discovery.
• ICON plc: Global CRO focused on clinical development with growing lab/biomarker services. Partial overlap with BioDuro on early development and bioanalytical services through its PRA Health combination.
• Syneos Health: Global clinical and commercial CRO. Overlaps BioDuro on biotech client base and drug development services though weighted toward clinical operations.
• IQVIA: Largest global CRO with full clinical and R&D services portfolio plus data/technology capabilities. Overlaps BioDuro on preclinical and lab services as a broader portfolio player.
• Labcorp / Fortrea (Covance spin): Major US clinical/preclinical CRO with global lab services. Comparable in early development CRO and bioanalytical offerings, though oriented more toward clinical scale.

Direct peers

• WuXi AppTec: China-headquartered, fully integrated CRDMO offering discovery, manufacturing, and clinical services globally. Direct competitor with overlapping one-stop-shop positioning, comparable China footprint, and similar breadth across modalities including ADC and PROTAC.
• Charles River Laboratories: Global preclinical CRO/CDMO with strong discovery, safety assessment, and biologics manufacturing franchises. Directly comparable in preclinical CRO, DMPK, and biologics capabilities though with a heavier US/EU footprint.
• Pharmaron: China-rooted, UK-/US-extended CRDMO providing laboratory, CMC, and biologics services. Closest comparable in operating model (China cost base + US/UK delivery) and end-to-end discovery-to-manufacturing scope.
• Hangzhou Tigermed: China-headquartered clinical and preclinical CRO serving global pharma and biotech. Comparable in target customer base and China-based delivery, with growing discovery CRO capability similar to BioDuro.
• Frontage Holdings: US-listed CRO/CDMO with integrated lab and CMC services and significant China operations. Comparable in discovery bioanalytical, DMPK, and drug substance scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sundia-meditech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sundia MediTech